Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 May;32(5):885-894.
doi: 10.1177/09622802231158738. Epub 2023 Mar 15.

Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect

Affiliations
Clinical Trial

Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect

Mu Shan et al. Stat Methods Med Res. 2023 May.

Abstract

The "one-size-fits-all'' paradigm is inappropriate for phase II clinical trials evaluating biotherapies, which are often expected to have substantial heterogeneous treatment effects among different subgroups defined by biomarker. For these biotherapies, the objective of phase II clinical trials is often to evaluate subgroup-specific treatment effects. In this article, we propose a simple yet efficient Bayesian adaptive phase II biomarker-guided design, referred to as the Bayesian-order constrained adaptive design, to detect the subgroup-specific treatment effects of biotherapies. The Bayesian order constrained adaptive design combines the features of the enrichment design and sequential design. It starts with a "all-comers" stage, and subsequently switches to an enrichment stage for either the marker-positive subgroup or marker-negative subgroup, depending on the interim analysis results. The go/no go enrichment criteria are determined by two posterior probabilities utilizing the inherent ordering constraint between two subgroups. We also extend the Bayesian-order constrained adaptive design to handle the missing biomarker situation. We conducted comprehensive computer simulation studies to investigate the operating characteristics of the Bayesian order constrained adaptive design, and compared it with other existing and conventional designs. The results shown that the Bayesian order constrained adaptive design yielded the best overall performance in detecting the subgroup-specific treatment effects by jointly considering the efficiency and cost-effectiveness of the trials. The software for simulation and trial implementation are available for free download.

Keywords: Phase II clinical trials; interim analysis; marker-guided design; missing data; sequential design.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Diagram of the BOCA design. The red boxes indicating the interim analysis steps that trigger the enrichment stage.
Figure 2:
Figure 2:
Power of BOCA-C, BOCA-DA and BOCA-O designs under various missing rates with p0=0.2 and ϕ=0.4.

References

    1. Friedman LM, Furberg CD, DeMets DL. (2010) Fundamentals of Clinical Trials Springer.
    1. Berry SM, Carlin BP, Lee JJ, Muller P. (2010) Bayesian Adaptive Methods for Clinical Trials CRC Press.
    1. Piantadosi S (2017) Clinical Trials: A Methodologic Perspective Wiley.
    1. Wu HC, Chang DK, Huang CT. (2006) Targeted therapy for cancer. Journal of Cancer Molecules, 2: 57–66.
    1. Leen AM, Rooney CM, Foster AE. (2009) Improving T cell therapy for cancer. Annual Review of Immunology, 25:243–265. - PubMed

Publication types